Santiago-Lagunes LM, Ríos-Gallardo PT, Perea-Martínez A, Lara-Campos AG, González-Valadez AL, García-Osorio V, Hernández-López MA, Solís-Aguilar DC, de la Paz-Morales C, de la Osa-Busto M, Reyes- Gómez U

Language: Spanish
References: 10
Page: 116-120
PDF size: 261.89 Kb.

ABSTRACT

Globally it is known that 25% of the adult population in the world has Non-Alcoholic Fatty Liver (NAFL), and it is estimated that up to 30% of subjects progress to Non- Alcoholic Steatohepatitis (NASH), for this reason since 2004, the number of adults with complications due to this disease almost tripled in the US and are awaiting a liver transplant, with NASH being the second most common indication only being exceeded by the hepatitis C virus, estimating that in the following 10 to 20 years complications due to NASH will be the fi rst cause of liver transplantation. According to recent systematic reviews and meta-analyzes, the average pooled prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) in children from studies in the general population has been found to be 7.6% and 34.2% in children with obesity from clinical studies. In adults with NASH, approximately 15% to 20% developed fi brosis and cirrhosis, but there are no long-term equivalent follow-up studies in children. Th e prevalence varies according to the detection method, which may include the measurement of alanine aminotransferase (ALT), images for steatosis, or confi rmation by liver biopsy.
It is also known that Dyslipidemia has a strong association with the development of this disease, in our country 3 out of 10 Mexicans suff er from it. Hypercholesterolemia, hypertriglyceridemia and mixed dyslipidemia are also risk factors for cardiovascular diseases which are among the fi rst four causes of mortality in Mexico.
For all the above it is vital to learn to recognize this entity in its early stages and how we can intervene in each of them. However, prevention must be the strongest pillar to prevent this disease from occurring.

REFERENCES

1. Vega J. Alteraciones en la homeostasis del colesterol hepático y sus implicaciones en la esteatohepatitis no alcohólica. TIP Revista Especializada en Ciencias Químico-Biológicas 2017; 20(1): 50-65.

2. Perla F, Prelati M, Lavorato M, Visicchio D, Anania C. The Role of Lipid and Lipoprotein Metabolism in Non-Alcoholic Fatty Liver Disease. Children 2017; 4: 46 doi:10.3390/ children4060046.

3. Sendensky A. Chronic Liver Failure. 2011; 5: 33–46. Available from: http://link.springer.com/10.1007/978-1-60761-866-9

4. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. United States; 1999;116(6): 1413–9.

5. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology. United States; 1999; 29(3): 664–9.

6. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest. United States; 2005; 115(5): 1343–51.

7. Lusting R. Fructose: Metabolic, Hedonic, and Societal Parallels with Ethanol. J Am Diet Assoc. 2010; 110: 1307-21.

8. Stanhope KL, Bremer AA, Medici V, Nakajima K, Ito Y, Nakano T, et al. Consumption of fructose and high fructose corn syrup increase postprandial triglycerides, LDL-Cholesterol, and apolipoprotein-B in Young men and women. J Clin Endocrinol Metab. 2011; 96(10): 1596-605.

9. Tappy L, Le K, Tran C, Paquot N. Fructose and metabolic diseases: New fi ndings, new questions, Nutrition. 2010; 26: 1044–9.

10. Vos M, Abrams S, Barlow S, Caprio S, Daniels S, et al. NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children: Recommendations from the Expert Committe on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). JPGN 2017; 64(2): 5-15